A 9 Week, Randomised, Double Blind, Placebo Controlled Study to Investigate the Effect of ZD4522 on Endothelial Function in Patients with Moderate Hypercholesterolaemia.

Study identifier:4522IL/0037

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 9 Week, Randomised, Double Blind, Placebo Controlled Study to Investigate the Effect of ZD4522 on Endothelial Function in Patients with Moderate Hypercholesterolaemia.

Medical condition

dyslipidaemia

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Aug 1999
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria